T2 Biosystems, Inc.

NasdaqCM:TTOO Stock Report

Market Cap: US$8.6m

T2 Biosystems Management

Management criteria checks 3/4

T2 Biosystems' CEO is John Sperzel, appointed in Jan 2020, has a tenure of 4.92 years. total yearly compensation is $865.50K, comprised of 66.4% salary and 33.6% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $163.92. The average tenure of the management team and the board of directors is 5.9 years and 7.8 years respectively.

Key information

John Sperzel

Chief executive officer

US$865.5k

Total compensation

CEO salary percentage66.4%
CEO tenure4.9yrs
CEO ownership0.002%
Management average tenure5.9yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Apr 18
Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

Oct 13

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

Sep 29

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

CEO Compensation Analysis

How has John Sperzel's remuneration changed compared to T2 Biosystems's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$48m

Mar 31 2024n/an/a

-US$46m

Dec 31 2023US$866kUS$575k

-US$50m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$2mUS$575k

-US$62m

Sep 30 2022n/an/a

-US$64m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$563k

-US$49m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$3mUS$491k

-US$47m

Compensation vs Market: John's total compensation ($USD865.50K) is above average for companies of similar size in the US market ($USD650.40K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Sperzel (61 yo)

4.9yrs

Tenure

US$865,500

Compensation

Mr. John J. Sperzel, III, B.Sc., serves as Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020 and has been its Chairman since July 23, 2021 and serves as President. Mr. Sperz...

Leadership Team

NamePositionTenureCompensationOwnership
John Sperzel
President4.9yrsUS$865.50k0.0019%
$ 163.9
John Sprague
Chief Financial Officer6.9yrsUS$581.00k0.00067%
$ 57.8
Michael Gibbs
Senior VP8.9yrsUS$622.60k0.00064%
$ 55.2
Kelley Morgan
Chief People Officer10.8yrsno datano data
Brett Giffin
Chief Commercial Officer3.1yrsno data0.00037%
$ 31.9
Roger Smith
Senior Vice President of Science Research & Development2.8yrsno datano data

5.9yrs

Average Tenure

60yo

Average Age

Experienced Management: TTOO's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Sperzel
President4.9yrsUS$865.50k0.0019%
$ 163.9
Robin Toft
Independent Director4.5yrsUS$60.00k0.00027%
$ 23.3
Seymour E. Liebman
Independent Director8.3yrsUS$40.00k0.00040%
$ 34.5
John Cumming
Lead Independent Director10.4yrsUS$96.00k0.00025%
$ 21.6
David Elsbree
Independent Director10.4yrsUS$60.00k0.00011%
$ 9.5
Eric Rosenberg
Member of Clinical Advisory Board13.6yrsno datano data
Louis Rice
Member of Clinical Advisory Board13.6yrsno datano data
Ninfa Saunders
Independent Director4.5yrsUS$50.00k0.00035%
$ 30.2
Peter Pappas
Member of Clinical Advisory Board13.6yrsno datano data
Michael Pfaller
Member of Clinical Advisory Board7.3yrsUS$1.10mno data
Laura Adams
Independent Director3.2yrsUS$40.00k0.00021%
$ 18.1
Sean Zhang
Member of Scientific Advisory Board2.7yrsno datano data

7.8yrs

Average Tenure

72.5yo

Average Age

Experienced Board: TTOO's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 02:27
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

T2 Biosystems, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Benjamin HaynorAlliance Global Partners
Karen KoskiBTIG
Kyle MiksonCanaccord Genuity